Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Bristol-Myers Squibb Company's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $125.6B | |
|---|---|---|
| Revenue (ttm) | 49.2B | |
| Net income (ttm) | 9.3B | |
| EPS (ttm) | $4.54 | |
| Shares out | 2B | |
| P/E (trailing) | 13.3x | |
| P/E (forward) | 9.4x | |
| Dividend | $2.52 (4.16%) | |
| Volume | 5,399,402 | |
| Beta | 0.18 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $46.39B | $46.16B | $45.01B | $48.30B | $48.19B | +1.0% |
| Gross profit | $26.76B | $26.49B | $25.36B | $27.43B | $34.26B | +6.4% |
| Operating income | $9.43B | $8.95B | $9.61B | $-6.43B | $11.22B | +4.4% |
| Net income | $6.99B | $6.33B | $8.03B | $-8.95B | $7.05B | +0.2% |
| EPS (diluted) | $3.12 | $2.95 | $3.86 | $-4.41 | $3.46 | +2.6% |
| EBITDA | $20.12B | $19.22B | $19.37B | $3.17B | $15.23B | -6.7% |
| R&D | $10.20B | $9.51B | $9.30B | $11.16B | $9.95B | -0.6% |
| SG&A | $7.69B | $7.81B | $7.77B | $8.41B | $7.27B | -1.4% |
Recent company headlines from major financial publishers.
The Base scenario represents the central projection with an assessed probability of 50.0%, establishing Fair value at $42.47, which represents an expected return of -31.4% relative to the share price of $61.94. This projection reflects steady commercial adoption across the growth portfolio alongside anticipated top-line contraction in FY2027 following European patent expirations on Eliquis. Operating margins compress moderately as loss of exclusivity impacts pricing, while robust operating cash flows continue to cover scheduled debt maturities and the dividend. Disconfirmation would occur if top-line revenue contracts faster than guided step-down levels or if pipeline programs encounter unexpected clinical or regulatory delays.
Under the Bull scenario, which carries an assessed probability of 20.0%, intrinsic value reaches Potential value of $52.68, representing an upside return of -14.9% from the share price of $61.94. This path requires rapid commercial scaling across newly commercialized specialty biopharmaceuticals alongside positive pivotal Phase Three trial readouts for late-stage therapies such as milvexian. Full-year revenue performance must show immediate volume expansion that more than offsets generic erosion, while international commercial execution stabilizes realization. Disconfirmation would occur if clinical development schedules experience delays in patient enrollment or if competitive specialty therapies limit commercial penetration.
| Ke ↓ / g → | 0.0% | 0.5% | 1.0% | 1.5% | 2.0% |
|---|---|---|---|---|---|
| 5.4% | $47.4 | $48.9 | $50.7 | $53.1 | $56.1 |
| 6.4% | $43.7 | $44.7 | $45.9 | $47.4 | $49.1 |
| 7.4% | $41.0 | $41.7 | $42.5 | $43.4 | $44.6 |
| 8.4% | $38.7 | $39.3 | $39.8 | $40.5 | $41.3 |
| 9.4% | $36.9 | $37.3 | $37.8 | $38.2 | $38.8 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
